原发肿瘤部位对转移性结直肠癌贝伐珠单抗联合化疗疗效的影响。
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer.
机构信息
Istituto Oncologico Veneto (IRCCS), Via Gattamelata, 64, 35128, Padova, PD, Italy.
Duke University Medical Center, 10 Duke Medicine Circle, Durham, NC, 27710, USA.
出版信息
Br J Cancer. 2018 Dec;119(12):1451-1455. doi: 10.1038/s41416-018-0304-6. Epub 2018 Nov 29.
BACKGROUND
Two first-line (1L) bevacizumab trials showed the prognostic value of primary tumour location in metastatic colorectal cancer (mCRC). In this retrospective subgroup analysis, further analysis of the predictive effect of bevacizumab is presented.
METHODS
Patients with sidedness information from two randomised phase III studies of bevacizumab + chemotherapy (CT) vs CT as 1L mCRC treatment were analysed retrospectively.
RESULTS
Sidedness was determined in 1590 (27% right and 73% left) of 2214 patients. Progression-free survival was improved with bevacizumab + CT vs CT in right-sided (HR = 0.75; 95% CI 0.61, 0.93; p = 0.008) and left-sided (HR = 0.76; 95% CI 0.67, 0.86; p < 0.001) mCRC (pooled analysis). Similarly, overall survival was numerically improved with bevacizumab + CT vs CT in right-sided mCRC (HR = 0.82; 95% CI 0.65, 1.03; p = 0.085), and significantly improved in left-sided mCRC (HR = 0.85; 95% CI 0.74, 0.98; p = 0.028).
CONCLUSIONS
This analysis indicates that the effect of bevacizumab is independent of tumour location in mCRC.
背景
两项贝伐珠单抗一线（1L）试验表明转移性结直肠癌（mCRC）原发肿瘤位置具有预后价值。在这项回顾性亚组分析中，进一步分析了贝伐珠单抗的预测效果。
方法
对两项贝伐珠单抗联合化疗（CT）与 CT 作为 mCRC 一线治疗的随机 III 期研究中具有侧别信息的患者进行回顾性分析。
结果
2214 例患者中有 1590 例（右侧占 27%，左侧占 73%）确定了侧别。贝伐珠单抗联合 CT 与 CT 相比，右侧（HR=0.75；95%CI 0.61,0.93；p=0.008）和左侧（HR=0.76；95%CI 0.67,0.86；p<0.001）mCRC 的无进展生存期得到改善（汇总分析）。同样，贝伐珠单抗联合 CT 与 CT 相比，右侧 mCRC 的总生存期有改善的趋势（HR=0.82；95%CI 0.65,1.03；p=0.085），左侧 mCRC 的总生存期显著改善（HR=0.85；95%CI 0.74,0.98；p=0.028）。
结论
这项分析表明，贝伐珠单抗在 mCRC 中的疗效不依赖于肿瘤位置。
Zotero 插件